Developing biotherapeutics,
biobetters, and innovative products

What we do?

We develop an innovative human erythropoietin-based neurotherapeutic to meet the needs of millions of people around the world who suffer from central nervous systems conditions like Parkinson´s disease, Alzheimer´s disease, multiple sclerosis, stroke, among others; for which, nowadays there is no effective treatment.

How we do it?

Human erythropoietin (hEPO) is a widely used biotherapeutic for anemia treatment because it stimulates red blood cells production. Besides, hEPO has neuroprotective and neuroplastic activity. Nevertheless, when it is used as a neuropharmaceutical in patients who do not suffer from anemia, it causes erythropoietic activity-associated side effects. Thus, from BioSynaptica, we have developed hEPO-based neurotherapeutic candidates through an innovative idea, to block its undesired effect but preserving its neurotherapeutic potentiality.

Development of new hEPO variants through glycoengineering

In vitro and in vivo confirmation of their blocked erythropoietic activity

Confirmation of their potentiality to promote neuroplastic/neuroprotective action on neuron-derived primary cultures

Validation for their long-lasting circulation in blood

National phase patent request (after positive evaluation of patentability by PCT) in Europe, EEUU, and twelve other countries which represent the most promising markets